Aeterna Zentaris (NASDAQ:AEZS) Stock Price Crosses Above 200 Day Moving Average of $7.80

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $7.80 and traded as high as $8.41. Aeterna Zentaris shares last traded at $8.41, with a volume of 5,631 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Aeterna Zentaris in a research note on Friday. They set a “sell” rating for the company.

Aeterna Zentaris Trading Down 0.2 %

The stock’s 50 day moving average price is $8.19 and its two-hundred day moving average price is $7.82. The firm has a market capitalization of $10.13 million, a PE ratio of -0.56 and a beta of 1.60.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported ($4.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.88) by ($0.76). Aeterna Zentaris had a negative return on equity of 83.45% and a negative net margin of 760.32%. The business had revenue of $0.12 million for the quarter.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.